<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653208</url>
  </required_header>
  <id_info>
    <org_study_id>IM_hzVSF_v13-0001</org_study_id>
    <nct_id>NCT03653208</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers</brief_title>
  <official_title>Dose Blocked-randomized, Double-blind, Placebo Controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 After Intravenous Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneMed, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmuneMed, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety/tolerability and pharmacokinetic characteristics after single&#xD;
      intravenous (IV) administration of hzVSF-v13 (humanized Virus Suppressing Factor-variant 13)&#xD;
      in healthy male volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose blocked-randomized, double-blind, placebo controlled, single dose, dose-escalation study&#xD;
      to investigate the safety/tolerability and pharmacokinetic characteristics of hzVSF-v13 after&#xD;
      IV administration in healthy male volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Assessments by Vital Signs</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 336, 504, 672, 840, 1176, 1512, 1848, 2184 hours (post-dose)</time_frame>
    <description>Systolic Blood Pressure: ≤ 90 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 140 mmHg and increase from baseline ≥ 20 mmHg Diastolic Blood Pressure: ≤ 50 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 90 mmHg and increase from baseline ≥ 10 mmHg Heart Rate: ≤ 40 beats/min and decrease from baseline ≥ 20 beats/min, ≥ 100 beats/min and increase from baseline ≥ 20 beats/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Characteristics - Cmax (Concentration Maximum)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 336, 504, 672, 840, 1176, 1512, 1848, 2184 hours (post-dose)</time_frame>
    <description>Maximum observed Concentration of hzVSF-v13 from Day1 to Day92.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - AUClast (Area Under the Curve Last)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 336, 504, 672, 840, 1176, 1512, 1848, 2184 hours (post-dose)</time_frame>
    <description>Area under the plasma concentration from Day1 to time of last measurable concentration.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1 (hzVSF-v13 10mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (hzVSF-v13 20mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (hzVSF-v13 50mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (hzVSF-v13 100mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 (hzVSF-v13 200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 (hzVSF-v13 400mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7 (hzVSF-v13 800mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8 (hzVSF-v13 1200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group received a single placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hzVSF-v13</intervention_name>
    <description>Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)</description>
    <arm_group_label>Group 1 (hzVSF-v13 10mg)</arm_group_label>
    <arm_group_label>Group 2 (hzVSF-v13 20mg)</arm_group_label>
    <arm_group_label>Group 3 (hzVSF-v13 50mg)</arm_group_label>
    <arm_group_label>Group 4 (hzVSF-v13 100mg)</arm_group_label>
    <arm_group_label>Group 5 (hzVSF-v13 200mg)</arm_group_label>
    <arm_group_label>Group 6 (hzVSF-v13 400mg)</arm_group_label>
    <arm_group_label>Group 7 (hzVSF-v13 800mg)</arm_group_label>
    <arm_group_label>Group 8 (hzVSF-v13 1200mg)</arm_group_label>
    <other_name>a humanized monoclonal antibody (mAb)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males aged 19 to 45 years at the time of the screening visit&#xD;
&#xD;
          -  Individuals with a BMI of at least 18 kg/m2 and up to 27.0 kg/m2 weighed more than 55&#xD;
             kg and less than 90 kg at the time of the screening visit&#xD;
&#xD;
          -  Individuals deemed clinically healthy based on medical history, physical examination,&#xD;
             vital signs, electrocardiography (ECG), and appropriate clinical laboratory tests&#xD;
             (provided that individuals outside the normal range may participate subject to&#xD;
             investigator discretion)&#xD;
&#xD;
          -  Individuals who have agreed to use a medically acceptable method of dual contraception&#xD;
             and not to donate sperm from the first day until 30 days after the last day of&#xD;
             investigational product administration&#xD;
&#xD;
          -  Individuals who have voluntarily decided to participate in this clinical study and&#xD;
             have given written consent to comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with a clinically significant hepatic, renal, digestive, respiratory,&#xD;
             musculoskeletal, endocrine, neurologic, psychological, hematologic, oncologic,&#xD;
             cardiovascular, or other disease or history&#xD;
&#xD;
          -  Individuals with a clinically significant history of sensitivity to the components of&#xD;
             hzVSF-v13, drugs containing components of the same series, or other drugs (aspirin,&#xD;
             non-steroidal anti-inflammatory drugs, antibiotics, etc.)&#xD;
&#xD;
          -  Individuals testing positive in the immunogenicity test for hzVSF-v13 conducted during&#xD;
             screening&#xD;
&#xD;
          -  Individuals who have a history of drug abuse, or who turns out &quot;positive&quot; in test for&#xD;
             abuse-likely drugs in the urine drug screening test&#xD;
&#xD;
          -  Individuals with abnormal results for any of the following vital signs at the time of&#xD;
             the screening visit A. Systolic blood pressure: &lt; 90 mmHg or &gt; 140 mmHg B. Diastolic&#xD;
             blood pressure: &lt; 50 mmHg or &gt; 90 mmHg C. Heart rate: &lt; 50 bpm or &gt; 90 bpm&#xD;
&#xD;
          -  Individuals with abnormal results for any of the following ECG items at the time of&#xD;
             the screening visit A. PR (Pulse rate): &gt; 210 msec B. QRS complex : &gt; 120 msec * QRS&#xD;
             complex is the name for the combination of three of the graphical deflections seen on&#xD;
             a typical electrocardiogram (EKG or ECG) C. QTc (Corrected QT interval): &gt; 450 msec&#xD;
&#xD;
          -  Individuals who have participated in another clinical study or bioequivalence study in&#xD;
             the 3 months prior to the first day of administration&#xD;
&#xD;
          -  Individuals who have donated whole blood within the 2 months prior to the first day of&#xD;
             administration, or donated blood components or received blood within the 1 month prior&#xD;
             to the first day of administration&#xD;
&#xD;
          -  Individuals who have taken barbitals or other drug-metabolizing enzyme inducers or&#xD;
             inhibitors within the 1 month prior to screening&#xD;
&#xD;
          -  Individuals who have consumed grapefruit or caffeine-containing foods within 3 days of&#xD;
             the first administration, and individuals who are unable to avoid consuming&#xD;
             grapefruit-containing foods from 3 days prior to admission until the date of discharge&#xD;
&#xD;
          -  Individuals who have taken prescription drugs or oriental medications within 2 weeks&#xD;
             prior to the first day of administration, or who have taken over-the-counter (OTC)&#xD;
             drugs within the 1 week prior to the first day of administration (provided that&#xD;
             individuals who meet other requirements may participate in the clinical study subject&#xD;
             to investigator discretion)&#xD;
&#xD;
          -  Individuals who consume high amounts of caffeine or alcohol and individuals who are&#xD;
             heavy smokers (caffeine &gt; 5 units/day, alcohol &gt; 21 units/week (1 unit = 10 mL of pure&#xD;
             alcohol), smoking &gt; 10 cigarettes/day)&#xD;
&#xD;
          -  Individuals who are unable to eat meals provided by the institution&#xD;
&#xD;
          -  Individuals who have participated in the present study&#xD;
&#xD;
          -  Individuals who test positive (for hepatitis B, human immunodeficiency virus (HIV),&#xD;
             hepatitis C) on serological testing&#xD;
&#xD;
          -  Individuals with veins that are not suitable for intravenous catheter insertion or&#xD;
             multiple venipunctures&#xD;
&#xD;
          -  Individuals who do not agree to use a medically acceptable method of dual&#xD;
             contraception from the first day until 30 days after the last day of investigational&#xD;
             product administration&#xD;
&#xD;
          -  Other individuals deemed unsuitable as a subject by an investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine/Seoul National University Hospital Department of Clinical Pharmacology and Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2021</results_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03653208/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03653208/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (hzVSF-v13 10mg)</title>
          <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (hzVSF-v13 20mg)</title>
          <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (hzVSF-v13 50mg)</title>
          <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Group 4 (hzVSF-v13 100mg)</title>
          <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Group 5 (hzVSF-v13 200mg)</title>
          <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Group 6 (hzVSF-v13 400mg)</title>
          <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Group 7 (hzVSF-v13 800mg)</title>
          <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Group 8 (hzVSF-v13 1200mg)</title>
          <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="P9">
          <title>Placebo</title>
          <description>Placebo group received a single placebo on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (hzVSF-v13 10mg)</title>
          <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (hzVSF-v13 20mg)</title>
          <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (hzVSF-v13 50mg)</title>
          <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Group 4 (hzVSF-v13 100mg)</title>
          <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Group 5 (hzVSF-v13 200mg)</title>
          <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Group 6 (hzVSF-v13 400mg)</title>
          <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Group 7 (hzVSF-v13 800mg)</title>
          <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Group 8 (hzVSF-v13 1200mg)</title>
          <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Placebo</title>
          <description>Placebo group received a single placebo on Day 1.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="14"/>
            <count group_id="B10" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="6.7"/>
                    <measurement group_id="B2" value="32.0" spread="6.6"/>
                    <measurement group_id="B3" value="32.8" spread="5.6"/>
                    <measurement group_id="B4" value="31.8" spread="4.5"/>
                    <measurement group_id="B5" value="30.3" spread="7.2"/>
                    <measurement group_id="B6" value="27.8" spread="4.9"/>
                    <measurement group_id="B7" value="35.5" spread="5.5"/>
                    <measurement group_id="B8" value="32.3" spread="5.9"/>
                    <measurement group_id="B9" value="33.4" spread="6.5"/>
                    <measurement group_id="B10" value="32.3" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability Assessments by Vital Signs</title>
        <description>Systolic Blood Pressure: ≤ 90 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 140 mmHg and increase from baseline ≥ 20 mmHg Diastolic Blood Pressure: ≤ 50 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 90 mmHg and increase from baseline ≥ 10 mmHg Heart Rate: ≤ 40 beats/min and decrease from baseline ≥ 20 beats/min, ≥ 100 beats/min and increase from baseline ≥ 20 beats/min</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 336, 504, 672, 840, 1176, 1512, 1848, 2184 hours (post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (hzVSF-v13 10mg)</title>
            <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (hzVSF-v13 20mg)</title>
            <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (hzVSF-v13 50mg)</title>
            <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (hzVSF-v13 100mg)</title>
            <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (hzVSF-v13 200mg)</title>
            <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (hzVSF-v13 400mg)</title>
            <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Group 7 (hzVSF-v13 800mg)</title>
            <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Group 8 (hzVSF-v13 1200mg)</title>
            <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>Placebo group received placebo on Day 1 (single administration).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Assessments by Vital Signs</title>
          <description>Systolic Blood Pressure: ≤ 90 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 140 mmHg and increase from baseline ≥ 20 mmHg Diastolic Blood Pressure: ≤ 50 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 90 mmHg and increase from baseline ≥ 10 mmHg Heart Rate: ≤ 40 beats/min and decrease from baseline ≥ 20 beats/min, ≥ 100 beats/min and increase from baseline ≥ 20 beats/min</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Characteristics - Cmax (Concentration Maximum)</title>
        <description>Maximum observed Concentration of hzVSF-v13 from Day1 to Day92.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 336, 504, 672, 840, 1176, 1512, 1848, 2184 hours (post-dose)</time_frame>
        <population>Placebo group were not included in pharmacokinetic analysis set as the it was below the quantification limit.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (hzVSF-v13 10mg)</title>
            <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (hzVSF-v13 20mg)</title>
            <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (hzVSF-v13 50mg)</title>
            <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (hzVSF-v13 100mg)</title>
            <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (hzVSF-v13 200mg)</title>
            <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (hzVSF-v13 400mg)</title>
            <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Group 7 (hzVSF-v13 800mg)</title>
            <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Group 8 (hzVSF-v13 1200mg)</title>
            <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Characteristics - Cmax (Concentration Maximum)</title>
          <description>Maximum observed Concentration of hzVSF-v13 from Day1 to Day92.</description>
          <population>Placebo group were not included in pharmacokinetic analysis set as the it was below the quantification limit.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.47"/>
                    <measurement group_id="O2" value="4.38" spread="1.31"/>
                    <measurement group_id="O3" value="14.04" spread="2.35"/>
                    <measurement group_id="O4" value="27.26" spread="5.82"/>
                    <measurement group_id="O5" value="45.39" spread="7.43"/>
                    <measurement group_id="O6" value="99.00" spread="14.07"/>
                    <measurement group_id="O7" value="174.43" spread="26.66"/>
                    <measurement group_id="O8" value="268.09" spread="28.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1075</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Slope</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK - AUClast (Area Under the Curve Last)</title>
        <description>Area under the plasma concentration from Day1 to time of last measurable concentration.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 336, 504, 672, 840, 1176, 1512, 1848, 2184 hours (post-dose)</time_frame>
        <population>Placebo group were not included in pharmacokinetic analysis set as the it was below the quantification limit.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (hzVSF-v13 10mg)</title>
            <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (hzVSF-v13 20mg)</title>
            <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (hzVSF-v13 50mg)</title>
            <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (hzVSF-v13 100mg)</title>
            <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 (hzVSF-v13 200mg)</title>
            <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Group 6 (hzVSF-v13 400mg)</title>
            <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Group 7 (hzVSF-v13 800mg)</title>
            <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Group 8 (hzVSF-v13 1200mg)</title>
            <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK - AUClast (Area Under the Curve Last)</title>
          <description>Area under the plasma concentration from Day1 to time of last measurable concentration.</description>
          <population>Placebo group were not included in pharmacokinetic analysis set as the it was below the quantification limit.</population>
          <units>h·mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.74" spread="35.76"/>
                    <measurement group_id="O2" value="1264.31" spread="315.53"/>
                    <measurement group_id="O3" value="4554.13" spread="1143.05"/>
                    <measurement group_id="O4" value="8226.23" spread="2766.32"/>
                    <measurement group_id="O5" value="17386.38" spread="5362.11"/>
                    <measurement group_id="O6" value="39032.00" spread="7672.94"/>
                    <measurement group_id="O7" value="80395.46" spread="9269.87"/>
                    <measurement group_id="O8" value="102677.10" spread="25759.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0548</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Slope</param_type>
            <param_value>1.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 92 Days after dosing date (Day1).</time_frame>
      <desc>A total of 55 subjects were administered the investigational product, and a total of 52 cases of treatment emergent adverse events(TEAEs) were collected from 19 subjects (34.55%). There were no subjects that had reported serious adverse events. 4 cases of adverse events collected from 3 subjects were moderate, and all other adverse events were mild. There were no severe adverse events collected. The most common TEAE was oropharyngeal pain, 7 cases thereof were collected from 7 subjects (12.73%).</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (hzVSF-v13 10mg)</title>
          <description>Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (hzVSF-v13 20mg)</title>
          <description>Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (hzVSF-v13 50mg)</title>
          <description>Group 3 received a single 50mg dose of hzVSF-v13 on Day 1</description>
        </group>
        <group group_id="E4">
          <title>Group 4 (hzVSF-v13 100mg)</title>
          <description>Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Group 5 (hzVSF-v13 200mg)</title>
          <description>Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Group 6 (hzVSF-v13 400mg)</title>
          <description>Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Group 7 (hzVSF-v13 800mg)</title>
          <description>Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Group 8 (hzVSF-v13 1200mg)</title>
          <description>Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.</description>
        </group>
        <group group_id="E9">
          <title>Placebo</title>
          <description>Placebo group received placebo on Day 1 (single administration).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Byoungok Ahn</name_or_title>
      <organization>ImmuneMed Inc.</organization>
      <phone>+82-2-527-8391</phone>
      <email>ahnbo@immunemed.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

